Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New immunotherapy strategy can eliminate pancreatic tumors in mice

Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.

6 Aug 2021

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

The recent US Food and Drug Administration (FDA) approval of aducanumab – which has the potential to treat Alzheimer's disease – may provide a proof of concept that can be rapidly improved upon, writes Dennis Selkoe in this Perspective.

6 Aug 2021

Affinity maturation of SARS-CoV-2 antibodies make them more powerful and resistant to escape mutations

A new study in the journal Immunity shows in fascinating detail how antibodies elicited by this virus show affinity maturation, a process occurring by somatic hypermutation (SHM) in the lymphoid germinal centers, to become more specific in their recognition of antigens.

6 Aug 2021

Dialysis patients' response to COVID19 vaccine type

The researchers at Standford University evaluated the humoral vaccination response of 2,099 fully vaccinated patients undergoing dialysis.

5 Aug 2021

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive and viable option against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is published in the journal Advanced Therapeutics.

5 Aug 2021

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

Shuo Ma, MD, '00 PhD, associate professor of Medicine in the Division of Hematology and Oncology, was co-first author of the clinical trial published in Blood.

5 Aug 2021

COVID vaccines generate antibodies in saliva

Researchers in the United States and Canada have conducted a study showing that the vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) generate local antibody responses in the salivary gland that are independent of the systemic immune response.

5 Aug 2021

Vaccination may protect against SARS-CoV-2 infection at the eye surface

Researchers in Australia have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) induces key antibodies at the eye surface that may help to protect against the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Aug 2021

COVID-19 vaccination offers significant protection for solid organ transplant recipients

In a Brief Communication, published July 29, 2021 in the journal Transplant Infectious Disease, a team of physician-scientists at University of California San Diego School of Medicine found that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.

5 Aug 2021

Scientists urge increased attention to persistent COVID-19 infections in immunocompromised people

In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious Diseases at the University of North Carolina urged increased attention to persistent COVID-19 infections in immunocompromised people.

5 Aug 2021

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Researchers remain perplexed as to why some patients infected with SARS-CoV-2, the virus responsible for COVID-19, remain asymptomatic while other patients develop severe disease symptoms.

5 Aug 2021

A correlation study between time-from-vaccine and SARS-CoV-2 breakthrough infections

A new retrospective study compares the incidence rates of breakthrough infections between different time points at which individuals were vaccinated.

5 Aug 2021

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

In a paper recently uploaded to the preprint server bioRxiv* by Kulkarni et al. (August 3, 2021), the potential of vaccinia virus-based vaccines expressing the full-length SARS-CoV-2 spike protein is examined in mice and Syrian hamsters. The findings report that the vaccine generates high titers of neutralizing antibodies with good activity towards SARS-CoV-2 variants of concern.

5 Aug 2021

New study examines B cell receptor repertoires in COVID-19 patients

In a paper recently uploaded to the preprint server bioRxiv* by Kim et al. (August 2, 2021), the B cell receptor repertoire of 1,060 COVID-19 patients is compared to that of an equal number of healthy volunteers in a novel manner, utilizing computational deep-learning-based protein embedding techniques, which demonstrate a resolution capable of tracking the changes in immunity in an individual over the course of infection.

5 Aug 2021

Immunocompromised patients could be potential hosts for immune-escape mutants of SARS-CoV-2

In a recently published article in The New England Journal of Medicine, scientists have described how multi-mutational variants of SARS-CoV-2 may evolve in patients with immunosuppression.

5 Aug 2021

How does the mRNA/lipid nanoparticle platform promote protective adaptive immunity against SARS-CoV-2?

Modified mRNA combined with lipid nanoparticles may be beneficial in boosting adaptive immunity against SARS-CoV-2. Research led by Botond Z. Igyártó from Thomas Jefferson University’s Department of Microbiology and Immunology in Pennsylvania recently found that the lipid nanoparticles induce protective adaptive immune responses with antibody titers against lethal doses of the virus.

5 Aug 2021

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States and Canada have described the structural basis and mode of action for two monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2021

Antibody News and Research

Further Reading

New immunotherapy strategy can eliminate pancreatic tumors in mice

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

Affinity maturation of SARS-CoV-2 antibodies make them more powerful and resistant to escape mutations

Dialysis patients' response to COVID19 vaccine type

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

COVID vaccines generate antibodies in saliva

Vaccination may protect against SARS-CoV-2 infection at the eye surface

COVID-19 vaccination offers significant protection for solid organ transplant recipients

Scientists urge increased attention to persistent COVID-19 infections in immunocompromised people

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

A correlation study between time-from-vaccine and SARS-CoV-2 breakthrough infections

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

New study examines B cell receptor repertoires in COVID-19 patients

Immunocompromised patients could be potential hosts for immune-escape mutants of SARS-CoV-2

How does the mRNA/lipid nanoparticle platform promote protective adaptive immunity against SARS-CoV-2?

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Monoclonal antibody could inform development of pan-coronavirus vaccines

Study finds only 15% of rural health care workers have SARS-CoV-2 antibodies

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo